Rochester, Minnesota


Bartlett.Mark@mayo.edu Clinical Profile


Mark G. Bartlett, M.D., is a pediatric gastroenterologist who studies Clostridium difficile infections in children and novel ways to treat the infections, including fecal microbial transplant. A current clinical study is comparing the efficacy of fresh versus frozen donor stool for eradication of Clostridium difficile.

Dr. Bartlett is also collaborating in research with the adult pancreatitis group in a multisite study of the role of prostaglandins in chronic pancreatitis and the possible use of aspirin for halting the progression of this disease in children.

Focus areas

  • Fecal microbial transplant. Dr. Bartlett is conducting a prospective study to evaluate children between 1 and 18 years old undergoing fecal transplant to eradicate recurrent Clostridium difficile infections. The specific aim is to see if frozen stool from anonymous screened donors can be equally as effective as fresh stool from parents. Dr. Bartlett is also using inflammatory markers such as lactoferrin, alpha-1-antitrypsin and calprotectin to better identify which children will most benefit from fecal microbial transplant. A focus of his study has been to better characterize the success of fecal transplant in immunocompromised children and those with inflammatory bowel disease.
  • Chronic pancreatitis. Dr. Bartlett is participating in a multisite investigation of the pathophysiology of inflammation and fibrosis in chronic pancreatitis, specifically looking at validating pancreatic juice prostaglandin E2 levels as a biomarker for this disease. An additional study will assess the potential for aspirin to suppress prostaglandin E2 in the pancreatic juice.

Significance to patient care

Dr. Bartlett is hopeful that his Fecal Microbial Transplant study will help to refine techniques for treating children with recurrent Clostridium difficile infections. Ideally, the process will continue to be simplified so that more children have access to this important therapy. Chronic pancreatitis is rare but devastating, and has no current treatment options other than pain medication. The current study is essential to the development of new therapies targeting pancreatic inflammation.


See my publications


Primary Appointment

  1. Consultant, Division of Pediatric Gastroenterology and Hepatology, Department of Pediatric and Adolescent Medicine

Joint Appointment

  1. Consultant, Division of Gastroenterology and Hepatology, Department of Internal Medicine

Academic Rank

  1. Assistant Professor of Pediatrics


  1. Fellow - Pediatric Gastroenterology Department of Pediatrics, University of Minnesota
  2. Resident Department of Pediatrics, University of California, San Francisco
  3. MD School of Medicine, University of Rochester
  4. BA - Honors in Division of Humanities Swarthmore College

Mayo Clinic Footer